We are an alliance dedicated to transforming the study of brain disorders and accelerating better diagnostics, treatments and cures.
Dr. Haas founded Orion Bionetworks in July 2012 and serves as its CEO and President. Orion Bionetworks was transformed to Cohen Veterans Bioscience in 2015 to specifically dedicate research to improving the detection and treatment of post-traumatic stress (PTS) and traumatic brain injury (TBI) and related co-morbidities so that the burden of these conditions may be lessened on service members, veterans, and their families. Magali has over 15 years of pharmaceutical executive and clinical research experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in medical marketing, full clinical development, early development, and translational and biomarker sciences in psychiatry and neurology. She successfully filed NDAs in the US and Europe for risperidone indications in Autism, Adolescent Schizophrenia, Juvenile Bipolar Disorder and Conduct Disorders. She also led Development Teams evaluating compounds for Depression, Neuropathic Pain, Epilepsy, and Migraine Disorder. She served 3 years as Chief Science and Technology Officer for One Mind for Research, a nonprofit organization launched in May 2012 by Patrick J Kennedy. She orchestrated the launch of One Mind’s seminal programs, Apollo, an informatics research portal and, Gemini, an international TBI/PTSD research program. As an “intrapreneur” at J&J she established the first Neuroscience Translational Medicine & Integrative Solutions department, and co-founded the first Companion Diagnostics Center of Excellence as well as J&J’s Healthcare Innovation team. She serves on several advisory boards including Brain Canada, Prophase, Pear Therapeutics, PAASP and IMEC for nanoelectronics. Magali earned her BS in bioengineering from the University of Pennsylvania, an MS in biomedical engineering from Rutgers University, New Jersey, and her MD PhD with distinction in neuroscience from Albert Einstein College of Medicine, New York. Dr. Allyson T. Gage is a neuroscientist and drug development executive, who has over 18 years of experience leading teams in all phases of clinical development. She has been responsible for the overall strategic Allyson earned her BA from Rutgers College in New Brunswick, NJ and her MS and PhD in neuroscience from Albert Einstein College of Medicine, New York. Andreas Jeromin, PhD, has established research programs in translational neuroscience in both industry and biotech for the last 25 years and co-authored more than 200 publications. He has also been elected a member of the Dana Alliance for Brain Initiatives. Andreas Jeromin has led biomarker qualification programs in diagnostics and therapeutics in acute neurological injury and neurodegeneration in roles with increased responsibilities. This included several drug development program from proof-of-concept to a NINDS-supported phase III trial (Protect III). He has also provided leadership and several strategic biomarker initiatives in different roles as member of the SABs or steering committee such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , the Coalition against Major Diseases (CAMD) directed by the Critical Path Institute (C-PATH), the Alzheimer’s Association CSF QC and biomarker assay standardization and harmonization initiatives in other CNS disorders, including MS (Accelerated Cure), ALS and PD. He is the founder and CSO of Atlantic Biomarkers, LLC, and joined Quanterix, Inc. as scientific and medical advisor in 2014. Lee Lancashire, PhD has over 15 years of experience in machine learning and statistics. His PhD was focused on the development of artificial neural network based methodologies where he was involved in many of the first applications of neural nets to high dimensional datasets in bioinformatics. Prior to joining Cohen Veterans Bioscience, Lee spent over five years within the IP&Science business of Thomson Reuters where he established and led the machine learning and statistical data analysis team. Here he held global responsibility for managing and delivering analytical projects, serving the majority of the top 10 pharmaceutical companies, as well as government, academic and non-profit organizations. These projects focused on utilizing advanced machine learning approaches in the molecular profiling of disease for biomarker discovery, patient stratification and drug target identification. Lee completed his post-doctoral research in Biostatistics and Bioinformatics at the Paterson Institute for Cancer Research, a Cancer Research UK core facility. He has also worked as a bioinformatics project lead in personalized medicine and diagnostics companies CompanDX and Almac Diagnostics. He has published in over 30 key industry journals and holds several patents around the use of neural networks in the biomedical domain. Mr. Plowden’s career over the past 20+ years includes leadership roles in non-profit, government funded and commercial enterprises in which he has been instrumental in organizational growth and transformation. As CVB’s CFO, Dan will develop and oversee the Finance function as well as manage the Business Operations areas of the organization. Prior to joining CVB, Mr. Plowden led the finance and administration operations of Health Leads, a national non-profit focused on health equity and the social determinants of health. He previously served as CFO for a Contract Research Organization conducting epidemiology studies, device trials, and health disparities research in partnership with National Institutes of Health (NIH), Department of Defense (DOD) and commercial entities. Prior to that he was CFO and Treasurer for a multi-national consultancy which provided expert testimony in economics, finance, and regulation to corporations, law firms, and public agencies. Mr. Plowden has long been a contributor to the business community and actively builds new relationships to create new possibilities. Volunteer activities include being a member of the Healthcare Financial Management Association (HFMA), serving on the local Chapter’s Healthcare Transformation Conference Committee. He is also a member and past President of the Treasurers’ Club of Boston, and a former Board member of Financial Executives International (FEI) Boston Chapter. Dan earned his MBA from Boston College, and BSBA with concentration in Finance, summa cum laude, from Northeastern University. Thomas P. Oberst brings 35 years of computer systems experience in high tech and financial services, most recently as the CTO of Advanced Strategic Technology. He is providing vision and technical leadership in the area of Big Data and Cyber Security in support of Cohen Veterans Bioscience’s mission. His career has spanned 20 years in high tech working, mostly in research and product development for startups which were later purchased by Hewlett Packard and EMC. His more recent career was spent working in the Enterprise Architecture and Technology Group at Fidelity Investments, where he helped design, develop, and deploy some of the most advanced systems used anywhere in Financial Services. Tom has expertise in computer and server architecture, system design, development, systems engineering and deployment of secure, extremely scalable, globally deployable information infrastructure. Tom earned his BS in Electrical Engineering from Union College, and Master Degrees in Computer Science and Business from Rensselaer Polytechnic Institute and the Harvard Business School. Kathleen Syben is the office manager in New York City office. She also functions as the executive assistant to the CEO and the C-Suite leadership team. Kathleen has extensive experience in office administration that she has honed over the past 20 years. Previously, she held jobs in public relations and social media. Kathleen has a B.B.A. in international business, marketing and public relations from Temple University .Executive Leadership Team
Magali Haas, MD, PhD
CEO & President
View BioMagali Haas, MD, PhD
CEO & President
Allyson Gage, PhD
Chief Medical Officer
View BioAllyson Gage, PhD
Chief Medical Officer
and clinical development of small molecules, biologics, and cellular therapies for the treatment of central nervous
system disorders, including depression, alcohol dependence, Alzheimer’s dementia, neuropathic pain, traumatic brain injury, and spinal cord injury. Allyson has a proven track record in partnering with therapeutic area clinicians, US and International regulators, patient groups, and data scientists to translate pre-clinical information into human evaluation, to design informative clinical trial protocols, and ensure a regulatory path with approvable and clinically meaningful outcome measures. Prior to joining Cohen Veterans Bioscience, Allyson’s most recent experience was focused in the field of regenerative medicine, working toward the development of a therapeutic for spinal cord injury.
Andreas Jeromin, PhD
Chief Scientific Officer
View BioAndreas Jeromin, PhD
Chief Scientific Officer
Lee Lancashire, PhD
Chief Information Officer
View BioLee Lancashire, PhD
Chief Information Officer
In his free time Lee devotes time volunteering as a trustee for the Ichthyosis Support Group, a charity that supports individuals and families affected by a group of rare skin disorders.
Daniel Plowden, MBA
Chief Financial Officer
View BioDaniel Plowden, MBA
Chief Financial Officer
Thomas P. Oberst
Chief Technology Advisor (Consulting)
View BioThomas P. Oberst
Chief Technology Advisor (Consulting)
Kathleen Syben
Executive Assistant & Office Manager
View BioKathleen Syben
Office Manager, NYC Headquarters